Mike puts gray market peptides from Chinese sellers to the test. Tap through to see what he checks for and what he found.
Recap by typeshit. Full story at PEPtalks with Mike.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Roche is betting on ALK7, a target that could in theory cut fat while sparing lean mass. Arrowhead, Alnylam, GSK and Novo are chasing it too.
Targets include Astra Peptides, Texas Peptides and Striker Pharmacy. Lilly says it has referred over 200 people and businesses to the FDA, DOJ and state attorneys general.
Loading…